JP7219220B2 - 改善された血清アルブミン結合剤 - Google Patents

改善された血清アルブミン結合剤 Download PDF

Info

Publication number
JP7219220B2
JP7219220B2 JP2019538382A JP2019538382A JP7219220B2 JP 7219220 B2 JP7219220 B2 JP 7219220B2 JP 2019538382 A JP2019538382 A JP 2019538382A JP 2019538382 A JP2019538382 A JP 2019538382A JP 7219220 B2 JP7219220 B2 JP 7219220B2
Authority
JP
Japan
Prior art keywords
seq
compound
variable domain
serum albumin
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515518A (ja
JP2020515518A5 (enExample
Inventor
スターレンス，ステファニー
シュテッフェンゼン，ソレン
モリゾ，エリカ
セルドベル，アン
Original Assignee
アブリンクス エン．ヴェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリンクス エン．ヴェー． filed Critical アブリンクス エン．ヴェー．
Publication of JP2020515518A publication Critical patent/JP2020515518A/ja
Publication of JP2020515518A5 publication Critical patent/JP2020515518A5/ja
Priority to JP2022196232A priority Critical patent/JP7628996B2/ja
Application granted granted Critical
Publication of JP7219220B2 publication Critical patent/JP7219220B2/ja
Priority to JP2024204085A priority patent/JP2025026992A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019538382A 2017-01-17 2018-01-17 改善された血清アルブミン結合剤 Active JP7219220B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022196232A JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤
JP2024204085A JP2025026992A (ja) 2017-01-17 2024-11-22 改善された血清アルブミン結合剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762446988P 2017-01-17 2017-01-17
US62/446,988 2017-01-17
PCT/EP2018/051083 WO2018134235A1 (en) 2017-01-17 2018-01-17 Improved serum albumin binders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022196232A Division JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤

Publications (3)

Publication Number Publication Date
JP2020515518A JP2020515518A (ja) 2020-05-28
JP2020515518A5 JP2020515518A5 (enExample) 2021-01-07
JP7219220B2 true JP7219220B2 (ja) 2023-02-07

Family

ID=61521465

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538382A Active JP7219220B2 (ja) 2017-01-17 2018-01-17 改善された血清アルブミン結合剤
JP2022196232A Active JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤
JP2024204085A Pending JP2025026992A (ja) 2017-01-17 2024-11-22 改善された血清アルブミン結合剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022196232A Active JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤
JP2024204085A Pending JP2025026992A (ja) 2017-01-17 2024-11-22 改善された血清アルブミン結合剤

Country Status (21)

Country Link
US (2) US11414481B2 (enExample)
EP (3) EP4442707A3 (enExample)
JP (3) JP7219220B2 (enExample)
KR (2) KR102662499B1 (enExample)
CN (2) CN110191896B (enExample)
AU (2) AU2018209151B2 (enExample)
BR (1) BR112019014599A2 (enExample)
CA (1) CA3050575A1 (enExample)
DK (1) DK3571225T3 (enExample)
ES (1) ES2991459T3 (enExample)
FI (1) FI3571225T3 (enExample)
HR (1) HRP20241469T1 (enExample)
HU (1) HUE068790T2 (enExample)
IL (2) IL312292A (enExample)
LT (1) LT3571225T (enExample)
MX (2) MX2019008496A (enExample)
PT (1) PT3571225T (enExample)
RS (1) RS66117B1 (enExample)
SG (2) SG11201906264YA (enExample)
SI (1) SI3571225T1 (enExample)
WO (1) WO2018134235A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023025232A (ja) * 2017-01-17 2023-02-21 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PH12022550313A1 (en) * 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
MX2019008536A (es) * 2017-01-17 2019-09-10 Ablynx Nv Aglutinantes de albumina serica mejorados.
MX2022006880A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
KR20220111313A (ko) 2019-12-06 2022-08-09 아블린쓰 엔.브이. TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
TWI861302B (zh) 2019-12-09 2024-11-11 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
EP4126971A1 (en) 2020-03-30 2023-02-08 Ablynx N.V. Method for the production and purification of multivalent immunoglobulin single variable domains
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
EP4262985A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
PH12023500009A1 (en) 2020-12-18 2024-03-11 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
TW202415678A (zh) 2022-06-14 2024-04-16 比利時商艾伯霖克斯公司 靶向ｔ細胞受體的免疫球蛋白單可變結構域
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
EP4665755A1 (en) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
TW202448951A (zh) 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
KR102822958B1 (ko) * 2023-05-23 2025-06-20 대한민국(해양경찰청 해양경찰연구센터장) 고래 불법포획 감식용 신속진단키트
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
TW202515917A (zh) 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
TW202540188A (zh) 2023-12-01 2025-10-16 比利時商艾伯霖克斯公司 精準活化的多肽
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
TW202547857A (zh) * 2024-04-12 2025-12-16 美商派拉岡醫療公司 抗ｈａｓ抗體及其組合物
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026052756A1 (en) 2024-09-05 2026-03-12 Ablynx Nv Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
JP2010518062A (ja) 2007-02-08 2010-05-27 ドマンティス リミテッド 血清アルブミンに対する抗体単一可変ドメイン
JP2012503638A (ja) 2008-09-26 2012-02-09 ユセベ ファルマ ソシエテ アノニム 生物学的産物
JP2014520129A (ja) 2011-06-23 2014-08-21 アブリンクス エン．ヴェー． 血清アルブミンに結合するタンパク質

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
WO2006059108A2 (en) 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
CN101454344A (zh) 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
AU2008252853B2 (en) 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
AU2009248049B2 (en) 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
CN102574914A (zh) 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
SG188204A1 (en) 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PH12022550313A1 (en) * 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20150344568A1 (en) * 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) * 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
PH12014500380A1 (en) 2011-08-17 2022-05-02 Glaxo Group Ltd Modified proteins and peptides
US20130129727A1 (en) * 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
AU2016209247B2 (en) 2015-01-21 2021-02-25 Inhibrx Biosciences, Inc. Non-immunogenic single domain antibodies
ES2754427T3 (es) 2015-05-13 2020-04-17 Ablynx Nv Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
LT3374392T (lt) * 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
MX2019008536A (es) * 2017-01-17 2019-09-10 Ablynx Nv Aglutinantes de albumina serica mejorados.
KR102662499B1 (ko) 2017-01-17 2024-05-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
AR133903A1 (es) * 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
JP2010518062A (ja) 2007-02-08 2010-05-27 ドマンティス リミテッド 血清アルブミンに対する抗体単一可変ドメイン
JP2012503638A (ja) 2008-09-26 2012-02-09 ユセベ ファルマ ソシエテ アノニム 生物学的産物
JP2014520129A (ja) 2011-06-23 2014-08-21 アブリンクス エン．ヴェー． 血清アルブミンに結合するタンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANG HYEON-JU et al.，ISOLATION OF HUMAN ANTI-SERUM ALBUMIN FAB ANTIBODIES WITH AN EXTENDED SERUM-HALF LIFE，IMMUNOLOGY LETTERS，NL，ELSEVIER BV，2015年11月22日，VOL:169，PAGE(S):33 - 40，http://dx.doi.org/10.1016/j.imlet.2015.11.013

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023025232A (ja) * 2017-01-17 2023-02-21 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
JP7628996B2 (ja) 2017-01-17 2025-02-12 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤

Also Published As

Publication number Publication date
EP4442709A2 (en) 2024-10-09
JP2023025232A (ja) 2023-02-21
WO2018134235A1 (en) 2018-07-26
EP4442709A3 (en) 2024-12-25
KR102662499B1 (ko) 2024-05-02
EP4442707A2 (en) 2024-10-09
CN110191896B (zh) 2023-09-29
RU2019125831A3 (enExample) 2021-03-09
KR20240013861A (ko) 2024-01-30
HRP20241469T1 (hr) 2025-01-03
EP3571225B1 (en) 2024-08-07
EP4442707A3 (en) 2024-12-25
IL267894A (en) 2019-09-26
US11414481B2 (en) 2022-08-16
US20190367597A1 (en) 2019-12-05
JP7628996B2 (ja) 2025-02-12
CA3050575A1 (en) 2018-07-26
AU2018209151B2 (en) 2025-02-27
LT3571225T (lt) 2024-11-11
HUE068790T2 (hu) 2025-01-28
SG11201906264YA (en) 2019-08-27
JP2025026992A (ja) 2025-02-26
JP2020515518A (ja) 2020-05-28
AU2025203430A1 (en) 2025-06-05
IL267894B2 (en) 2024-10-01
AU2018209151A1 (en) 2019-07-25
EP3571225A1 (en) 2019-11-27
DK3571225T3 (da) 2024-11-04
SG10202108972RA (en) 2021-09-29
SI3571225T1 (sl) 2025-03-31
IL267894B1 (en) 2024-06-01
BR112019014599A2 (pt) 2020-03-03
US20230060574A1 (en) 2023-03-02
ES2991459T3 (es) 2024-12-03
CN110191896A (zh) 2019-08-30
IL312292A (en) 2024-06-01
RS66117B1 (sr) 2024-11-29
MX2019008496A (es) 2019-09-18
RU2019125831A (ru) 2021-02-19
PT3571225T (pt) 2024-11-05
MX2023005374A (es) 2023-05-22
KR20190104608A (ko) 2019-09-10
FI3571225T3 (fi) 2024-10-31
CN117285623A (zh) 2023-12-26
WO2018134235A8 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
JP7628996B2 (ja) 改善された血清アルブミン結合剤
JP7585272B2 (ja) 改善された血清アルブミン結合剤
HK40119626A (en) Improved serum albumin binders
HK40116819A (en) Improved serum albumin binders
HK40117444A (en) Improved serum albumin binders
HK40118030A (en) Improved serum albumin binders
HK40018516A (en) Improved serum albumin binders
HK40018516B (en) Improved serum albumin binders
HK40017968A (en) Improved serum albumin binders
HK40017968B (en) Improved serum albumin binders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221215

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230126

R150 Certificate of patent or registration of utility model

Ref document number: 7219220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250